Amlodipine Use in Stage 3a CKD

Blood Pressure Management in CKD

The American College of Cardiology recommends a blood pressure target of <130/80 mmHg for patients with Stage 3 CKD, and amlodipine is an appropriate agent to achieve this goal 1, 2
The American College of Cardiology supports intensive blood pressure management in CKD patients based on SPRINT trial data, where participants with stage 3-4 CKD who received intensive antihypertensive therapy derived the same beneficial reduction in cardiovascular events and all-cause mortality as those without CKD 1, 2
Amlodipine was as effective as chlorthalidone in reducing coronary heart disease and stroke in all categories except heart failure, according to the ALLHAT trial 3

Women display faster drug clearance of amlodipine than men due to higher CYP3A4 activity, but this clearance decreases with age, explaining why older women experience greater blood pressure reduction 4, 5
Peripheral edema, the most common side effect, occurs more frequently in women and may lead to decreased adherence 5

If the patient has albuminuria ≥300 mg/day, an ACE inhibitor or ARB should be the preferred first-line agent, with amlodipine added as second-line therapy if blood pressure remains uncontrolled 1, 2
When combining amlodipine with an ARB, some evidence suggests this combination may provide additional renoprotective effects beyond blood pressure reduction alone 7
The American College of Cardiology recommends not combining an ACE inhibitor with an ARB, as this increases adverse events without additional benefit 1

After initiating amlodipine, monitor blood pressure, serum creatinine, and electrolytes within 2-4 weeks, then every 3-6 months depending on stability, as recommended by Praxis Medical Insights 6
An initial small decline in GFR (10-20%) after starting any antihypertensive therapy is acceptable and does not require discontinuation unless accompanied by hyperkalemia or excessive decline 6, 8